82 related articles for article (PubMed ID: 1525610)
1. Intensive immunotherapy with recombinant IL2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections.
Blaise D; Stoppa AM; Viens P; Sainty D; Fossat C; Miquel M; Olive D; Bouabdallah R; Gabert J; Baume D
Bone Marrow Transplant; 1992 Aug; 10(2):193-4. PubMed ID: 1525610
[No Abstract] [Full Text] [Related]
2. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
Favrot MC; Floret D; Negrier S; Cochat P; Bouffet E; Zhou DC; Franks CR; Bijman T; Brunat-Mentigny M; Philip I
Bone Marrow Transplant; 1989 Sep; 4(5):499-503. PubMed ID: 2790327
[TBL] [Abstract][Full Text] [Related]
3. Incidence of bacterial contamination of bone marrow grafts.
Schepers KG; Davis JM; Rowley SD
Prog Clin Biol Res; 1992; 377():379-84. PubMed ID: 1438434
[No Abstract] [Full Text] [Related]
4. Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.
Negrier S; Ranchere JY; Philip I; Merrouche Y; Biron P; Blaise D; Attal M; Rebattu P; Clavel M; Pourreau C
Bone Marrow Transplant; 1991 Oct; 8(4):259-64. PubMed ID: 1756323
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in conjunction with autologous bone marrow transplantation.
Eckerstein A; Slavin S; Weiss L; Naparstek E
Bone Marrow Transplant; 1990 Jan; 5 Suppl 1():38. PubMed ID: 2317604
[TBL] [Abstract][Full Text] [Related]
6. [Adoptive immunotherapy with interleukin 2 in oncology].
Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
[TBL] [Abstract][Full Text] [Related]
7. Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy.
Toren A; Ackerstein A; Gazit D; Or R; Raveh D; Kupolovicz U; Engelhard D; Nagler A
Bone Marrow Transplant; 1996 Jul; 18(1):209-10. PubMed ID: 8832017
[TBL] [Abstract][Full Text] [Related]
8. [Prevention and treatment of bacterial infections in bone marrow transplantation].
Sanz Alonso MA; Jarque Ramos I
Rev Clin Esp; 1995 Oct; 195 Spec No():19-21. PubMed ID: 8948731
[No Abstract] [Full Text] [Related]
9. Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation.
Costello R; Blaise D; Jacquemier J; Monges G; Stoppa AM; Viens P; Olive D; Bouabdallah M; Brandely ; Gastaut JA
Bone Marrow Transplant; 1995 Jul; 16(1):199-200. PubMed ID: 7581125
[No Abstract] [Full Text] [Related]
10. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients.
Mossad SB; Longworth DL; Goormastic M; Serkey JM; Keys TF; Bolwell BJ
Bone Marrow Transplant; 1996 Aug; 18(2):265-71. PubMed ID: 8864433
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
12. Detection of bacterial contamination in bone marrow graft.
D'Antonio D; Iacone A; Fioritoni G; Dragani A; Betti S; Quaglietta AM; Di Gianfilippo R; Accorsi P; Recchia A; Di Girolamo A
Haematologica; 1991 Mar; 76 Suppl 1():44-5. PubMed ID: 1864553
[TBL] [Abstract][Full Text] [Related]
13. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
14. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
Klingemann HG; Eaves CJ; Barnett MJ; Eaves AC; Hogge DE; Nantel SH; Reece E; Shepherd JD; Sutherland HJ; Phillips GL
Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
[TBL] [Abstract][Full Text] [Related]
15. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
Bosly A; Brice P; Humblet Y; Doyen C; Faille A; Chatelain B; Franks C; Gisselbrecht C; Symann M
Nouv Rev Fr Hematol (1978); 1990; 32(1):13-6. PubMed ID: 2349079
[TBL] [Abstract][Full Text] [Related]
17. Bacterial contamination of autologous bone marrow: reinfusion of culture-positive grafts does not result in clinical sequelae during the posttransplantation course.
Schwella N; Rick O; Heuft HG; Miksits K; Zimmermann R; Zingsem J; Eckstein R; Huhn D
Vox Sang; 1998; 74(2):88-94. PubMed ID: 9501406
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
[TBL] [Abstract][Full Text] [Related]
19. Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study.
Michon J; Négrier S; Coze C; Mathiot C; Frappaz D; Oskam R; Pacquement H; Quintana E; Bouffet E; Bernard JL
Prog Clin Biol Res; 1994; 385():293-300. PubMed ID: 7972223
[No Abstract] [Full Text] [Related]
20. Granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjunct to autologous bone marrow transplantation (ABMT) in hematology. Results of the interim analysis of the Schering-Plough/Sandoz International trial and considerations on increased safety in the transplant ward.
Gorin NC; Fouillard L
Pathol Biol (Paris); 1992 Nov; 39(9):954-5. PubMed ID: 1538950
[No Abstract] [Full Text] [Related]
[Next] [New Search]
